The administration of small-dose etoposide for a long period as a maintenance therapy in the patients with non-Hodgikin's lynphoma
| Autor: | Takahiro Okamoto, Hajime Tago, Hiroshi Yamano, Katsuyasu Saigou, Ryouichi Ogawa, Akihisa Kanamaru, Shiro Nakayama, Eizo Kakisita, Nobuo Yamaguchi, Takayuki Takahashi, Masaru Nishikiori, Mitsunori Okada |
|---|---|
| Rok vydání: | 1995 |
| Předmět: | |
| Zdroj: | Journal of the Japan Society of the Reticuloendothelial System. 35:291-298 |
| ISSN: | 1883-6801 0386-9725 |
| DOI: | 10.3960/jslrt1961.35.291 |
| Popis: | We investigated whether the administration of small-dose etoposide for a long period of time as a post intensive therapy is effective on remission duration and survival of patients with non-Hodgkin's lymphoma. After complete remission following CHOP or VEPA therapy, 33 patients were registered and administered etoposide at a daily oral dose of 25mg/body for a long time (median days; 211). Twenty-seven patients who were treated without the maintenance therapy, were used as a historical control.The long-term complete remission ratio at 3 years was 54% for the etoposide group compared with 36% for the control group. Especially in patients over 65 years of age, the remission ratio was 61% for the etoposide group compared with 25% for the control group.The long-term survival ratio at 5 years was 67% for the etoposide group compared with 59% for the control group. The small-dose etoposide as a post intensive therapy seemingly showed a beneficial effect but not statistically significant on the remission duration (P=0.08, Generalized Wilcoxon test) and the survival length (P=0.96, Generalized Wilcoxon test).Side effects and abnormal laboratory findings were minimal in the etoposide group except one patient with leukopenia (grade 4).These preliminary data suggested the usefulness of the small-dose etoposide as a post intensive therapy for treatment of non-Hodgkin's lymphoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|